Podcast Episodes

Back to Search
Complement Therapeutics received IND clearance from U.S. FDA today to start a trial of its AAV gene therapy for geographic atrophy that delivers a truncated version of Complement Receptor 1 to the eye
Complement Therapeutics received IND clearance from U.S. FDA today to start a trial of its AAV gene therapy for geographic atrophy that delivers a truncated version of Complement Receptor 1 to the eye

CEO Rafiq Hasan describes to BiotechTV's Amy Brown during an interivew in London how this program works, and he compares and contrasts it to more tra…

11 months, 1 week ago

Short Long
View Episode
Align Summit: Cambridge based Quiver Bioscience is developing ASOs for CNS conditions, including having programs in the red hot Nav1.7/1.8 pain space
Align Summit: Cambridge based Quiver Bioscience is developing ASOs for CNS conditions, including having programs in the red hot Nav1.7/1.8 pain space

Co-Founder & CEO Graham Dempsey describes the different between Nav1.7 and 1.8, and why he thinks having an ASO approach will succeed in 1.7 where sm…

11 months, 1 week ago

Short Long
View Episode
Align Summit: Toronto based HDAX Therapeutics believes there are many indications to tackle with its dual binding approach to HDAC6
Align Summit: Toronto based HDAX Therapeutics believes there are many indications to tackle with its dual binding approach to HDAC6

Co-Founder & CEO Nabanita Nawar describes the need for tackle HDAC6 with better chemistry. Plus, what it is like being a biotech startup in Canada to…

11 months, 1 week ago

Short Long
View Episode
Align Summit: Allston based KiraGen Bio is aiming to program CAR-T cells to tune out the suppressive nature of the tumor micro environment. The first program will be for GBM.
Align Summit: Allston based KiraGen Bio is aiming to program CAR-T cells to tune out the suppressive nature of the tumor micro environment. The first program will be for GBM.

Co-Founder and CEO Aaron Edwards describes the rational behind this approach, as opposed charging the cells with cytokines or removing their brakes. …

11 months, 1 week ago

Short Long
View Episode
Soufflé Therapeutics exited stealth today with the goal of developing nucleic acid therapies, like siRNAs and ASOs, delivered to any cell in the body by targeting internalizing receptors
Soufflé Therapeutics exited stealth today with the goal of developing nucleic acid therapies, like siRNAs and ASOs, delivered to any cell in the body by targeting internalizing receptors

CEO Amir Nashat, who has decades of experience in biotech at Polaris Partners, describes the work Soufflé has been doing to catalogue often rare targ…

11 months, 1 week ago

Short Long
View Episode
Brian Alexander, former CEO of Foundation Medicine, describes how Valo Health is using its AI expertise to partner with companies and foundations on discovery and development projects
Brian Alexander, former CEO of Foundation Medicine, describes how Valo Health is using its AI expertise to partner with companies and foundations on discovery and development projects

The company recently received a grant from the Michael J. Fox Foundation to work on Parkinson's, and has existing partnerships with companies such as…

11 months, 2 weeks ago

Short Long
View Episode
Aerska launched in the UK today with $21M in financing to develop RNAi medicines for neurological conditions that are delivered to the brain via 'brain shuttle' technologies across the BBB
Aerska launched in the UK today with $21M in financing to develop RNAi medicines for neurological conditions that are delivered to the brain via 'brain shuttle' technologies across the BBB

Chief Executive Officer Jack O'Meara, who previously founded Ochre Bio in the RNA space, describes the potential benefits of using brain shuttles and…

11 months, 2 weeks ago

Short Long
View Episode
Enanta Pharmaceuticals' CEO and CMO discuss data announced today on the company's RSV treatment, Zelicapavir, and describe the road ahead for this program and the company
Enanta Pharmaceuticals' CEO and CMO discuss data announced today on the company's RSV treatment, Zelicapavir, and describe the road ahead for this program and the company

CEO Jay Luly and CMO Scott Rottinghaus describe today's data, which was focused on high risk adults. They explain how safety and efficacy were measur…

11 months, 2 weeks ago

Short Long
View Episode
Sunny Kumar, a partner at Informed Ventures, and an active investor in the AI space, talks about current and future implications of AI's impact on healthcare
Sunny Kumar, a partner at Informed Ventures, and an active investor in the AI space, talks about current and future implications of AI's impact on healthcare

He discussed how current technologies are making healthcare more effecient today, how new technologies are opening new markets, and how the practice …

11 months, 3 weeks ago

Short Long
View Episode
Eko Health's Co-Founder & CEO shows BiotechTV the company's digital stethoscope and explains how having both an electric and sound component can help physicians catch heart disease (and more) earlier
Eko Health's Co-Founder & CEO shows BiotechTV the company's digital stethoscope and explains how having both an electric and sound component can help physicians catch heart disease (and more) earlier

Connor Landgraf shows us the product and describes recent data the company compiled in the UK showing the benefits of using this digital and AI enhan…

11 months, 4 weeks ago

Short Long
View Episode

Love PodBriefly?

If you like Podbriefly.com, please consider donating to support the ongoing development.

Support Us